The large study looked at people with both schizophrenia and diabetes taking drugs like Ozempic. Quartz notes the findings come with caveats.
Recap by typeshit. Post by @qz on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Reuters reports on a growing field of developers racing into obesity drugs as competition gets tighter.
Fierce Pharma's weekly tracker, using IQVIA data via Citi and Jefferies, has Zepbound still far ahead at about 801.8K total scripts.
Loading…